WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8174-8182

  Morrison, Debra J ^a   English, Milton A ^b   Licht, Jonathan D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAK; PROTEIN BCL 2; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VOLTAGE GATED CHANNEL FORMING PROTEIN; VOLTAGE GATED CHANNEL FORMING PROTEIN 2; WT1 PROTEIN;

APOPTOSIS; ARTICLE; BINDING SITE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; EMBRYO DEVELOPMENT; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY DEVELOPMENT; MESENCHYME; MISSENSE MUTATION; MULTIPOTENT STEM CELL; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FAMILY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, NEOPLASM; GENES, WILMS TUMOR; HUMANS; MICE; MUTATION, MISSENSE; OSTEOSARCOMA; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATION (GENETICS); WILMS TUMOR; WT1 PROTEINS;

EID: 24944496261     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3657     Document Type: Article

References (51)

1. Matsunaga E. Genetics of Wilms' tumor. Hum Genet 1981;57:231-46.
2. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
3. Little M, Holmes G, Walsh P. WT1: what has the last decade told us? Bioessays 1999;21:191-202.
4. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
5. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms tumours of a gene identified by chromosome jumping. Nature 1990;343:774-8.
6. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991;67:437-47.
7. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-25.
8. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development Cell 1993;74:679-91.
9. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE, Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci U S A 1991;88:9618-22.
10. Rauscher FJ III, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990;250:1259-62.
11. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995;81:391-401.
12. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998;12:3217-25.
13. Hewitt SM, Fraizer GC, Wu YJ, Rauscher F Jr, Saunders GF. Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation. J Biol Chem 1996;271:8588-92.
14. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 1991;253:1550-3.
15. Lee SB, Huang K, Palmer R, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999;98:663-73.
16. Gross I, Morrison DJ, Hyink DP, et al. The receptor tyrosine kinase regulator Sproutyl is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem 2003;278:41420-30.
17. Basson MA, Akbulut S, Watson-Johnson J, et al. Sproutyl is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell 2005;8:229-39.
18. Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol 2004;15:3044-51.
19. Guo G, Morrison DJ, Licht JD, Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. J Am Soc Nephrol 2004;152851-6.
20. Shamberger RC. Pediatric renal tumors. Semin Surg Oncol 1999;16:105-20.
21. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-49.
22. Bouillet P, Strasser A. BH3-only proteins-evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 2002;115:1567-74.
23. Reed JC, Doctor KS, Godzik A. The domains of apoptosis: a genomics perspective. Sci STKE 2004;2004:re9.
24. English M, Licht J. Tumor-associated WT1 missense mutants indicate that transcriptional activation is essential for growth control. J Biol Chem 1999;274:13258-63.
25. Sharma PM, Bowman M, Yu BF, Sukumar S. A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N′-methylurea, Proc Natl Acad Sci U S A 1994;91:9931-5.
26. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14:4662-75.
27. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003;301:513-7.
28. Reddy JC, Morris JC, Wang J, et al. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995;270:10878-84.
29. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett 2004;149:19-23.
30. Ulrich E, Kauffmann-Zeh A, Hueber AO, et al. Gene structure, cDNA sequence, and expression of murine Bak, a proapoptotic Bcl-2 family member. Genomics 1997;44:195-200.
31. Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 1996;56:2849-55.
32. Nakagama H, Heinrich G, Pelletier J, Housman DE. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol 1995;15:1489-98.
33. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999;18:3990-4003.
34. Pearson AS, Spitz FR, Swisher SG, et al. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in iung cancer cells. Clin Cancer Res 2000;6:887-90.
35. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
36. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
37. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
38. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
39. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002;9:505-12.
40. Haber DA, Park S, Maheswaran S, et al. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 1993;262:2057-9.
41. Luo XN, Reddy JC, Yeyati PL, et al. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene 1995;11:743-50.
42. McMaster ML, Gessler M, Stanbridge EJ, Weissman BE. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line. Cell Growth Differ 1995;6:1609-17.
43. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003;4:321-8.
44. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ III, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995;55:5386-9.
45. Heckman C, Mochon E, Arcinas M, Boxer LM. The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. J Biol Chem 1997;272:19609-14.
46. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003;278:19995-20005.
47. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 2004;7:125-37.
48. Rusconi JC, Fink JL, Cagan R. Klumpfuss regulates cell death in the Drosophila retina. Mech Dev 2004;121:537-46.
49. Gross I, Bassit B, Benezra M, Licht JD. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 2001;276:46460-8.
50. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 1990;10:1-36.
51. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998;79:268-73.